aTyr Pharma, Inc. Common Stock
ATYRaTyr Pharma, Inc. is a biotechnology company focused on developing innovative therapies targeting rare and severe diseases, particularly those involving neuroinflammation and immune modulation. The company's approach involves designing molecules that can restore or maintain healthy cellular functions, with an emphasis on the nervous and immune systems.
Company News
aTyr Pharma announced it will advance efzofitimod development in pulmonary sarcoidosis following a Type C FDA meeting. The company plans to submit an IND in June 2026 for a Phase 3 study using FVC as primary endpoint and KSQ-Lung as secondary endpoint. The company ended Q1 2026 with $68.3 million in cash and is on track to complete enrollment in ...
The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive ...
Hagens Berman is pursuing a securities class action lawsuit against aTyr Pharma after its flagship drug trial failed, causing an 83% stock price collapse. The lawsuit alleges the company misrepresented the efficacy of its drug Efzofitimod and concealed material adverse facts about its performance.
A class action lawsuit has been filed against aTyr Pharma alleging false and misleading statements about the efficacy of their drug Efzofitimod, with investors having until December 8, 2025 to apply as lead plaintiff.
Rosen Law Firm alerts ATyr Pharma investors about a securities class action lawsuit deadline on December 8, 2025, related to allegedly misleading statements about the effectiveness of the drug Efzofitimod.
